Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Vickers Venture Partners

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 53
Average round size
The average size of a deal this fund participated in
Portfolio companies 27
Rounds per year 3.12
Lead investments 16
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 1
Key employees 6
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Mobile
  • E-Commerce
  • FinTech

In 2005 was created Vickers Venture Partners, which is appeared as VC. The venture was found in Asia in Singapore. The leading representative office of defined VC is situated in the Singapore.

The top activity for fund was in 2019. The increased amount of exits for fund were in 2019. The typical startup value when the investment from Vickers Venture Partners is more than 1 billion dollars. The fund is constantly included in 2-6 deals per year. The usual things for fund are deals in the range of 10 - 50 millions dollars. Considering the real fund results, this VC is 35 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Vickers Venture Partners performs on 24 percentage points less the average number of lead investments.

For fund there is no match between the location of its establishment and the land of its numerous investments - United States. The fund has no exact preference in some founders of portfolio startups. When startup sums 3 or 5+ of the founder, the probability for it to get the investment is little. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Software, Mobile. Among the most popular portfolio startups of the fund, we may highlight Samumed, Skyroam, Chooch AI.

The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Vickers Venture Partners, startups are often financed by GSR Ventures, Wavemaker Partners, SPH Media Fund. The meaningful sponsors for the fund in investment in the same round are GSR Ventures, Wavemaker Partners, WI Harper Group. In the next rounds fund is usually obtained by JAFCO Asia, GSR Ventures, Wavemaker Partners.

We also calculated 6 valuable employees in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Vickers Venture Partners:
Typical Co-investors
Vickers Venture Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Vickers Venture Partners:

Funds with similar focus

Funds from Singapore
Funds with similar focus located in Singapore:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

RWDC Industries

Advanced Materials
$95M22 Nov 2021 Singapore, Central, Singapore

Aardvark Therapeutics

Health Care
$29M05 Aug 2021 San Diego, California, United States


Clean Energy
Renewable Energy
$40M16 Feb 2021 Canada


Health Care
$13M26 Nov 2020 Belfast, Northern Ireland, United Kingdom

Chooch AI

Artificial Intelligence
Computer Vision
Facial Recognition
Image Recognition
Machine Learning
$20M16 Nov 2020 California, United States


Media and Entertainment
07 Sep 2020 Jakarta, Jakarta Raya, Indonesia

MatchMove Pay

Cloud Computing
Financial Services
Gift Card
Information Technology
Mobile Payments
$21M04 Sep 2020 Singapore, Central, Singapore

Spark Systems

Financial Services
Venture Capital
$11M15 May 2020 Central

RWDC Industries

Advanced Materials
$133M05 May 2020 Singapore, Central, Singapore
Aardvark Therapeutics Closes $29M Series B Funding

– Aardvark Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing novel small molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
– The company completed a $29m Series B financing.
– The round was led by Sorrento Therapeutics with participation from existing investors including Vickers Venture Partners, Premier Partners, BNH Investment, and Korea Omega.
– The funds raised will be deployed to advance the company’s pipeline of programs for metabolic diseases.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Vickers Venture Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: